P2NB34 Stock Overview
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Penumbra, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$38.22 |
| 52 Week High | US$54.60 |
| 52 Week Low | US$31.30 |
| Beta | 0.54 |
| 1 Month Change | 0% |
| 3 Month Change | 0.55% |
| 1 Year Change | -14.57% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -4.80% |
Recent News & Updates
Recent updates
Shareholder Returns
| P2NB34 | BR Medical Equipment | BR Market | |
|---|---|---|---|
| 7D | 0% | 0.5% | 0.9% |
| 1Y | -14.6% | -1.8% | 15.2% |
Return vs Industry: P2NB34 underperformed the BR Medical Equipment industry which returned 4.5% over the past year.
Return vs Market: P2NB34 underperformed the BR Market which returned 13.1% over the past year.
Price Volatility
| P2NB34 volatility | |
|---|---|
| P2NB34 Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 6.6% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in BR Market | 8.9% |
| 10% least volatile stocks in BR Market | 2.2% |
Stable Share Price: P2NB34 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine P2NB34's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 3,900 | Adam Elsesser | www.penumbrainc.com |
Penumbra, Inc., together with its subsidiairies, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, SENDit, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System, Lightning, and CAT RX brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names.
Penumbra, Inc. Fundamentals Summary
| P2NB34 fundamental statistics | |
|---|---|
| Market cap | R$51.82b |
| Earnings (TTM) | R$201.52m |
| Revenue (TTM) | R$4.94b |
257.1x
P/E Ratio10.5x
P/S RatioIs P2NB34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| P2NB34 income statement (TTM) | |
|---|---|
| Revenue | US$995.06m |
| Cost of Revenue | US$360.98m |
| Gross Profit | US$634.08m |
| Other Expenses | US$593.47m |
| Earnings | US$40.61m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Feb 22, 2024
| Earnings per share (EPS) | 1.05 |
| Gross Margin | 63.72% |
| Net Profit Margin | 4.08% |
| Debt/Equity Ratio | 0% |
How did P2NB34 perform over the long term?
See historical performance and comparison